{
  "links": "https://www.ycombinator.com/companies/ochre-bio",
  "name": "Ochre Bio",
  "headline": "RNA medicines for liver diseases",
  "batch": "W20",
  "description": "Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.",
  "activity_status": "Active",
  "website": "https://www.ochre-bio.com/",
  "founded_date": 2019.0,
  "team_size": 50.0,
  "location": "Oxford, United Kingdom",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:biotech; industry:genomics",
  "founders": [],
  "status": true,
  "markdown": "raw_markdown='[Skip to content](https://www.ochre-bio.com/<#content>)\\n[ ![](https://www.ochre-bio.com/wp-content/uploads/2022/02/Group-4.svg) ](https://www.ochre-bio.com/<https:/www.ochre-bio.com>)\\n  * [What](https://www.ochre-bio.com/</#what>)\\n  * [Why](https://www.ochre-bio.com/</#why>)\\n  * [How](https://www.ochre-bio.com/</#how>)\\n  * [Who](https://www.ochre-bio.com/</#who>)\\n  * [More](https://www.ochre-bio.com/</#more>)\\n\\n\\n  * [What](https://www.ochre-bio.com/</#what>)\\n  * [Why](https://www.ochre-bio.com/</#why>)\\n  * [How](https://www.ochre-bio.com/</#how>)\\n  * [Who](https://www.ochre-bio.com/</#who>)\\n  * [More](https://www.ochre-bio.com/</#more>)\\n\\n\\n[ ![](https://www.ochre-bio.com/wp-content/uploads/2022/02/Group-4.svg) ](https://www.ochre-bio.com/<https:/www.ochre-bio.com>)\\n  * [What](https://www.ochre-bio.com/</#what>)\\n  * [Why](https://www.ochre-bio.com/</#why>)\\n  * [How](https://www.ochre-bio.com/</#how>)\\n  * [Who](https://www.ochre-bio.com/</#who>)\\n  * [More](https://www.ochre-bio.com/</#more>)\\n\\n\\n  * [What](https://www.ochre-bio.com/</#what>)\\n  * [Why](https://www.ochre-bio.com/</#why>)\\n  * [How](https://www.ochre-bio.com/</#how>)\\n  * [Who](https://www.ochre-bio.com/</#who>)\\n  * [More](https://www.ochre-bio.com/</#more>)\\n\\n\\n## Ochre Ideas\\n[ VIEW ALL ](https://www.ochre-bio.com/</ideas>)\\n## Rethinking liver therapy discovery and development \\n\"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence.\" \\nDr. Chinwe Ukomadu, MD, PhDSenior Vice President and Head, Gastrointestinal and Inflammation Therapeutic Area Unit at Takeda, Ochre Bio Board Observer\\n“The scale of Ochre\\'s work is uniquely powered to address the complexities of liver disease.” \\nScott Friedman, MDChief, Division of Liver DiseasesIcahn School of Medicine at Mount Sinai \\n\"Ochre embodies an unprecedented convergence of computational and multi-omic technologies. Truly a next-generation platform for solving liver disease.\" \\nJoel Dudley, PhDPartner at Innovation Endeavors\\n\"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence.\" \\nDr. Chinwe Ukomadu, MD, PhDSenior Vice President and Head, Gastrointestinal and Inflammation Therapeutic Area Unit at Takeda, Ochre Bio Board Observer\\n“The scale of Ochre\\'s work is uniquely powered to address the complexities of liver disease.” \\nScott Friedman, MDChief, Division of Liver DiseasesIcahn School of Medicine at Mount Sinai \\n![](https://www.ochre-bio.com/wp-content/uploads/2022/04/liver-data-aura.png)\\ncellular senescence \\nmacroautophagy \\nbeta oxidation \\nde novo lipogenesis \\nER stress \\nintrinsic apoptosis \\nglucose metabolism \\n\"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence.\" \\nDr. Chinwe Ukomadu, MD, PhDSenior Vice President and Head, Gastrointestinal and Inflammation Therapeutic Area Unit at Takeda, Ochre Bio Board Observer\\n“The scale of Ochre\\'s work is uniquely powered to address the complexities of liver disease.” \\nScott Friedman, MDChief, Division of Liver DiseasesIcahn School of Medicine at Mount Sinai \\n\"Ochre embodies an unprecedented convergence of computational and multi-omic technologies. Truly a next-generation platform for solving liver disease.\" \\nJoel Dudley, PhDPartner at Innovation Endeavors\\n\"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence.\" \\nDr. Chinwe Ukomadu, MD, PhDSenior Vice President and Head, Gastrointestinal and Inflammation Therapeutic Area Unit at Takeda, Ochre Bio Board Observer\\n“The scale of Ochre\\'s work is uniquely powered to address the complexities of liver disease.” \\nScott Friedman, MDChief, Division of Liver DiseasesIcahn School of Medicine at Mount Sinai \\n## WHAT\\n## Using human models to generate genomic and phenotypic data at scale, we\\'re developing RNA therapies for the biggest liver health challenges.\\n## WHY\\n## Chronic liver disease is the only top ten global killer on the rise.\\n## \"Liver disease is the third leading cause of premature death.\" [UK Health Security Agency, July 2021](https://www.ochre-bio.com/<https:/gateway.euro.who.int/en/datasets/european-health-for-all-database/>)\\nChronic liver disease affects millions of patients worldwide, with the prevalence rising. Despite the recent first approval of a therapy for MASH, a high unmet need remains for patients with late stage disease, where for many patients the only treatment remains a liver transplant.\\n[ ![](https://www.ochre-bio.com/wp-content/uploads/2022/03/Group-18-1024x633.png) ](https://www.ochre-bio.com/<https:/live-ochrebio.pantheonsite.io/wp-content/uploads/2022/03/Group-18.png>)\\n[European Health for All database](https://www.ochre-bio.com/<https:/gateway.euro.who.int/en/datasets/european-health-for-all-database/>). Data missing in 2000.\\n## HOW\\n![](https://www.ochre-bio.com/wp-content/uploads/2024/09/discovery-1-scaled.jpg)\\n## Human Discovery\\nWe deep phenotype human liver samples and models at scale to causally map genes to cells to histology and clinical data.\\n![](https://www.ochre-bio.com/wp-content/uploads/2024/09/validation-1024x768.jpg)\\n## Human Validation\\nOchre’s validation platform is among the world’s most advanced in human systems, from human cell co-culture, to diseased liver tissue culture, to the perfusion of whole human livers.\\n![](https://www.ochre-bio.com/wp-content/uploads/2024/09/rna-1024x771.jpg)\\n## RNA Therapies\\nOur RNA chemistry platform not only develops therapies with a greater chance of clinical success, it allows Ochre’s scientists to progress a target to a validated lead using human data in weeks, not years.\\n## WHO\\n## Built on decades of leading genomics, ML, drug discovery and development experience, Ochre Bio’s scientific teams are committed to addressing unmet needs for patients with chronic liver disease globally. \\nAll\\nDry Lab\\nWet Lab\\nChem Lab\\nOrgan Lab\\nNo Lab\\nBoard and SAB\\nAll\\n## Massoud Malang\\nHead of IT and Cybersecurity \\n## Kayla Lawrence\\nResearch Associate \\n## Mark Lundquist\\nHead of Late Stage Validation \\n## Rosalind Schilizzi\\nResearch Associate \\n## Claudia Zagami\\nScientist \\n## Sarah Cooper-Pinchbeck\\nPeople and Culture Lead \\n## Sarah Batey\\nHead of Portfolio Development and Scientific Ops \\n## Guillaume Noell\\nPrincipal Scientist \\n## Yunke Zhou\\nResearch Associate I \\n## Su-Han Mao\\nResearch Associate I \\n[ Load More ](https://www.ochre-bio.com/<#>)\\nDry Lab\\n## Guillaume Noell\\nPrincipal Scientist \\n## Ludo Wesolowski\\nSenior Scientist \\n## Ran Li\\nSenior Scientist \\n## Raphael Castellan\\nSenior Scientist \\n## Anthony Beucher\\nPrincipal Scientist \\nWet Lab\\n## Ana Cuervo\\nPrincipal Scientist \\n## Ashley Hoffland\\nScientist \\n## Chi-An Li\\nResearch Associate \\n## Cho-Chin Cheng\\nScientist II \\n## Claudia Zagami\\nScientist \\n## Edward O’Neill\\nScientist \\n## Ellen Kuo\\nSenior Scientist \\n## Esther Arnaiz Gonzalez\\nScientist \\n## Fabio Sanna\\nHead of Innovation \\n## Ines Mateus\\nScientist \\n[ Load More ](https://www.ochre-bio.com/<#>)\\nChem Lab\\n## Sachin Patil\\nSenior Scientist \\n## Michal Matuszewski\\nScientist \\n## Fleur Palmer-Paquis\\nScientist \\n## Robert Mart\\nHead of Lead Development \\n## Calum Irwin\\nScientist \\n## Nick Taylor\\nSenior Scientist \\nOrgan Lab\\n## Ahmad Bashir Barekzai\\nClinical Research Scientist \\n## Amita Gupta\\nScientist \\n## Joanne Soong\\nLab Manager \\n## Kayla Lawrence\\nResearch Associate \\n## Kelly Tompeck\\nClinical Research Lead \\n## Mark Lundquist\\nHead of Late Stage Validation \\n## Mateo Noriega\\nClinical Research Scientist \\n## Nicola de Prisco\\nScientist \\n## Owen Reilly\\nScientist \\n## Sannidhi Joshipura\\nResearch Associate \\n[ Load More ](https://www.ochre-bio.com/<#>)\\nNo Lab\\n## Francesca Flintoft-Burt\\nProgram Manager \\n## Jack Castle\\nHead of Corporate Development & Business Operations \\n## Massoud Malang\\nHead of IT and Cybersecurity \\n## Paul Foster\\nHead of Legal \\n## Sarah Batey\\nHead of Portfolio Development and Scientific Ops \\n## Sarah Cooper-Pinchbeck\\nPeople and Culture Lead \\n## Shaysha Rastogi\\nExecutive & Team Assistant \\n## Stephanie Barnett-Dean\\nHead of Finance \\nBoard and SAB\\n## Alex K. Shalek\\nSAB Member \\n## Chas Bountra\\nSAB Member \\n## Chinwe Ukomadu\\nSSB Member & Board Observer \\n## Eduardo Martins\\nSAB Member \\n## Eliot Forster\\nExecutive Chairperson \\n## Leanne Hodson\\nSAB Member \\n## Michael Hodges\\nSAB Member \\n## Ness Bermingham\\nBoard Member \\n## Peter Friend\\nSAB member \\n## Quin Wills\\nFounder, CSO \\n[ Load More ](https://www.ochre-bio.com/<#>)\\n  * [ All ](https://www.ochre-bio.com/<javascript:;>)\\n  * [ BOARD & SAB ](https://www.ochre-bio.com/<javascript:;>)\\n  * [ Chem lab ](https://www.ochre-bio.com/<javascript:;>)\\n  * [ Dry Lab ](https://www.ochre-bio.com/<javascript:;>)\\n  * [ No Lab ](https://www.ochre-bio.com/<javascript:;>)\\n  * [ Organ lab ](https://www.ochre-bio.com/<javascript:;>)\\n  * [ Wet Lab ](https://www.ochre-bio.com/<javascript:;>)\\n\\n\\n##  [ Massoud Malang ](https://www.ochre-bio.com/<https:/www.ochre-bio.com/team/massoud-malang/>)\\nHead of IT and Cybersecurity\\n##  [ Kayla Lawrence ](https://www.ochre-bio.com/<https:/www.ochre-bio.com/team/kayla-lawrence/>)\\nResearch Associate\\n##  [ Mark Lundquist ](https://www.ochre-bio.com/<https:/www.ochre-bio.com/team/mark-lundquist/>)\\nHead of Late Stage Validation\\n##  [ Rosalind Schilizzi ](https://www.ochre-bio.com/<https:/www.ochre-bio.com/team/rosalind-schilizzi/>)\\nResearch Associate\\n1 [2](https://www.ochre-bio.com/<https:/www.ochre-bio.com/page/2/>) [3](https://www.ochre-bio.com/<https:/www.ochre-bio.com/page/3/>) … [17](https://www.ochre-bio.com/<https:/www.ochre-bio.com/page/17/>) [Next »](https://www.ochre-bio.com/<https:/www.ochre-bio.com/page/2/>)\\n## MORE\\n## News & Announcements\\n[ VIEW ALL ](https://www.ochre-bio.com/</news/>)\\n[ ![](https://www.ochre-bio.com/wp-content/uploads/2021/12/fierce-biotech-logo-1.png) ](https://www.ochre-bio.com/</news>)\\n# [GSK signs AI pact with Ochre to pinpoint source of liver diseases](https://www.ochre-bio.com/<https:/www.ochre-bio.com/news/>)\\n  * June 12, 2024\\n\\n\\n[ ![](https://www.ochre-bio.com/wp-content/uploads/2024/05/17b6c9ac-7097-40fd-8f34-2f7117fd646b_aboutus-FT.jpg-1024x578.webp) ](https://www.ochre-bio.com/</news>)\\n# [UK biotech signs $1bn deal to develop liver disease drugs](https://www.ochre-bio.com/<https:/www.ochre-bio.com/news/>)\\n  * April 22, 2024\\n\\n\\n[ ![](https://www.ochre-bio.com/wp-content/uploads/2024/05/EndpointsNews_logo.jpg) ](https://www.ochre-bio.com/</news>)\\n# [Boehringer Ingelheim inks chronic liver disease research pact with Ochre Bio](https://www.ochre-bio.com/<https:/www.ochre-bio.com/news/>)\\n  * April 22, 2024\\n\\n\\n[ VIEW ALL ](https://www.ochre-bio.com/</news/>)\\n## PARTNERS & INVESTORS\\n## Ochre Ideas\\n[ VIEW ALL ](https://www.ochre-bio.com/</ideas>)\\n## Think you’d like to **join our team?**\\nCheck out our [open positions](https://www.ochre-bio.com/</careers/>) or ask us to hold your CV at jobs@ochre-bio.com\\n## Work at Ochre\\n[ WATCH VIDEO ](https://www.ochre-bio.com/<#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjU0NjciLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D>)\\n![](https://live-ochrebio.pantheonsite.io/wp-content/uploads/2022/02/Group-4.svg)\\n## [Subscribe for Updates](https://www.ochre-bio.com/<#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMzNDkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D>)\\n**More** [Careers](https://www.ochre-bio.com/</Careers-at-ochre>) [News](https://www.ochre-bio.com/</news/>)\\n**Contact**\\n**Locations**\\nOxford, UK\\nTaipei City, Taiwan\\nNew York City, NY\\n**Contact** contact@ochre-bio.com\\n## [Subscribe for Updates](https://www.ochre-bio.com/<#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMzNDkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D>)\\n[ ](https://www.ochre-bio.com/<https:/twitter.com/OchreBio?s=20&t=idTeGMQtVFOqBVlpDeMepA>) [ Linkedin-in ](https://www.ochre-bio.com/<https:/www.linkedin.com/company/ochre-bio/>)\\n© 2024 Ochre Bio\\n  * All Rights Reserved \\n  * All Regular Disclaimers Apply \\n  * [ Privacy Policy  ](https://www.ochre-bio.com/</privacy-policy>)\\n\\n\\n' markdown_with_citations='Skip to content⟨1⟩\\n ![⟨2⟩ ](https://www.ochre-bio.com/<https:/www.ochre-bio.com>)\\n  * What⟨3⟩\\n  * Why⟨4⟩\\n  * How⟨5⟩\\n  * Who⟨6⟩\\n  * More⟨7⟩\\n\\n\\n  * What⟨3⟩\\n  * Why⟨4⟩\\n  * How⟨5⟩\\n  * Who⟨6⟩\\n  * More⟨7⟩\\n\\n\\n ![⟨2⟩ ](https://www.ochre-bio.com/<https:/www.ochre-bio.com>)\\n  * What⟨3⟩\\n  * Why⟨4⟩\\n  * How⟨5⟩\\n  * Who⟨6⟩\\n  * More⟨7⟩\\n\\n\\n  * What⟨3⟩\\n  * Why⟨4⟩\\n  * How⟨5⟩\\n  * Who⟨6⟩\\n  * More⟨7⟩\\n\\n\\n## Ochre Ideas\\n VIEW ALL ⟨8⟩\\n## Rethinking liver therapy discovery and development \\n\"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence.\" \\nDr. Chinwe Ukomadu, MD, PhDSenior Vice President and Head, Gastrointestinal and Inflammation Therapeutic Area Unit at Takeda, Ochre Bio Board Observer\\n“The scale of Ochre\\'s work is uniquely powered to address the complexities of liver disease.” \\nScott Friedman, MDChief, Division of Liver DiseasesIcahn School of Medicine at Mount Sinai \\n\"Ochre embodies an unprecedented convergence of computational and multi-omic technologies. Truly a next-generation platform for solving liver disease.\" \\nJoel Dudley, PhDPartner at Innovation Endeavors\\n\"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence.\" \\nDr. Chinwe Ukomadu, MD, PhDSenior Vice President and Head, Gastrointestinal and Inflammation Therapeutic Area Unit at Takeda, Ochre Bio Board Observer\\n“The scale of Ochre\\'s work is uniquely powered to address the complexities of liver disease.” \\nScott Friedman, MDChief, Division of Liver DiseasesIcahn School of Medicine at Mount Sinai \\n![](https://www.ochre-bio.com/wp-content/uploads/2022/04/liver-data-aura.png)\\ncellular senescence \\nmacroautophagy \\nbeta oxidation \\nde novo lipogenesis \\nER stress \\nintrinsic apoptosis \\nglucose metabolism \\n\"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence.\" \\nDr. Chinwe Ukomadu, MD, PhDSenior Vice President and Head, Gastrointestinal and Inflammation Therapeutic Area Unit at Takeda, Ochre Bio Board Observer\\n“The scale of Ochre\\'s work is uniquely powered to address the complexities of liver disease.” \\nScott Friedman, MDChief, Division of Liver DiseasesIcahn School of Medicine at Mount Sinai \\n\"Ochre embodies an unprecedented convergence of computational and multi-omic technologies. Truly a next-generation platform for solving liver disease.\" \\nJoel Dudley, PhDPartner at Innovation Endeavors\\n\"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence.\" \\nDr. Chinwe Ukomadu, MD, PhDSenior Vice President and Head, Gastrointestinal and Inflammation Therapeutic Area Unit at Takeda, Ochre Bio Board Observer\\n“The scale of Ochre\\'s work is uniquely powered to address the complexities of liver disease.” \\nScott Friedman, MDChief, Division of Liver DiseasesIcahn School of Medicine at Mount Sinai \\n## WHAT\\n## Using human models to generate genomic and phenotypic data at scale, we\\'re developing RNA therapies for the biggest liver health challenges.\\n## WHY\\n## Chronic liver disease is the only top ten global killer on the rise.\\n## \"Liver disease is the third leading cause of premature death.\" UK Health Security Agency, July 2021⟨9⟩\\nChronic liver disease affects millions of patients worldwide, with the prevalence rising. Despite the recent first approval of a therapy for MASH, a high unmet need remains for patients with late stage disease, where for many patients the only treatment remains a liver transplant.\\n ![⟨10⟩ ](https://www.ochre-bio.com/<https:/live-ochrebio.pantheonsite.io/wp-content/uploads/2022/03/Group-18.png>)\\nEuropean Health for All database⟨9⟩. Data missing in 2000.\\n## HOW\\n![](https://www.ochre-bio.com/wp-content/uploads/2024/09/discovery-1-scaled.jpg)\\n## Human Discovery\\nWe deep phenotype human liver samples and models at scale to causally map genes to cells to histology and clinical data.\\n![](https://www.ochre-bio.com/wp-content/uploads/2024/09/validation-1024x768.jpg)\\n## Human Validation\\nOchre’s validation platform is among the world’s most advanced in human systems, from human cell co-culture, to diseased liver tissue culture, to the perfusion of whole human livers.\\n![](https://www.ochre-bio.com/wp-content/uploads/2024/09/rna-1024x771.jpg)\\n## RNA Therapies\\nOur RNA chemistry platform not only develops therapies with a greater chance of clinical success, it allows Ochre’s scientists to progress a target to a validated lead using human data in weeks, not years.\\n## WHO\\n## Built on decades of leading genomics, ML, drug discovery and development experience, Ochre Bio’s scientific teams are committed to addressing unmet needs for patients with chronic liver disease globally. \\nAll\\nDry Lab\\nWet Lab\\nChem Lab\\nOrgan Lab\\nNo Lab\\nBoard and SAB\\nAll\\n## Massoud Malang\\nHead of IT and Cybersecurity \\n## Kayla Lawrence\\nResearch Associate \\n## Mark Lundquist\\nHead of Late Stage Validation \\n## Rosalind Schilizzi\\nResearch Associate \\n## Claudia Zagami\\nScientist \\n## Sarah Cooper-Pinchbeck\\nPeople and Culture Lead \\n## Sarah Batey\\nHead of Portfolio Development and Scientific Ops \\n## Guillaume Noell\\nPrincipal Scientist \\n## Yunke Zhou\\nResearch Associate I \\n## Su-Han Mao\\nResearch Associate I \\n Load More ⟨11⟩\\nDry Lab\\n## Guillaume Noell\\nPrincipal Scientist \\n## Ludo Wesolowski\\nSenior Scientist \\n## Ran Li\\nSenior Scientist \\n## Raphael Castellan\\nSenior Scientist \\n## Anthony Beucher\\nPrincipal Scientist \\nWet Lab\\n## Ana Cuervo\\nPrincipal Scientist \\n## Ashley Hoffland\\nScientist \\n## Chi-An Li\\nResearch Associate \\n## Cho-Chin Cheng\\nScientist II \\n## Claudia Zagami\\nScientist \\n## Edward O’Neill\\nScientist \\n## Ellen Kuo\\nSenior Scientist \\n## Esther Arnaiz Gonzalez\\nScientist \\n## Fabio Sanna\\nHead of Innovation \\n## Ines Mateus\\nScientist \\n Load More ⟨11⟩\\nChem Lab\\n## Sachin Patil\\nSenior Scientist \\n## Michal Matuszewski\\nScientist \\n## Fleur Palmer-Paquis\\nScientist \\n## Robert Mart\\nHead of Lead Development \\n## Calum Irwin\\nScientist \\n## Nick Taylor\\nSenior Scientist \\nOrgan Lab\\n## Ahmad Bashir Barekzai\\nClinical Research Scientist \\n## Amita Gupta\\nScientist \\n## Joanne Soong\\nLab Manager \\n## Kayla Lawrence\\nResearch Associate \\n## Kelly Tompeck\\nClinical Research Lead \\n## Mark Lundquist\\nHead of Late Stage Validation \\n## Mateo Noriega\\nClinical Research Scientist \\n## Nicola de Prisco\\nScientist \\n## Owen Reilly\\nScientist \\n## Sannidhi Joshipura\\nResearch Associate \\n Load More ⟨11⟩\\nNo Lab\\n## Francesca Flintoft-Burt\\nProgram Manager \\n## Jack Castle\\nHead of Corporate Development & Business Operations \\n## Massoud Malang\\nHead of IT and Cybersecurity \\n## Paul Foster\\nHead of Legal \\n## Sarah Batey\\nHead of Portfolio Development and Scientific Ops \\n## Sarah Cooper-Pinchbeck\\nPeople and Culture Lead \\n## Shaysha Rastogi\\nExecutive & Team Assistant \\n## Stephanie Barnett-Dean\\nHead of Finance \\nBoard and SAB\\n## Alex K. Shalek\\nSAB Member \\n## Chas Bountra\\nSAB Member \\n## Chinwe Ukomadu\\nSSB Member & Board Observer \\n## Eduardo Martins\\nSAB Member \\n## Eliot Forster\\nExecutive Chairperson \\n## Leanne Hodson\\nSAB Member \\n## Michael Hodges\\nSAB Member \\n## Ness Bermingham\\nBoard Member \\n## Peter Friend\\nSAB member \\n## Quin Wills\\nFounder, CSO \\n Load More ⟨11⟩\\n  *  All ⟨12⟩\\n  *  BOARD & SAB ⟨12⟩\\n  *  Chem lab ⟨12⟩\\n  *  Dry Lab ⟨12⟩\\n  *  No Lab ⟨12⟩\\n  *  Organ lab ⟨12⟩\\n  *  Wet Lab ⟨12⟩\\n\\n\\n##   Massoud Malang ⟨13⟩\\nHead of IT and Cybersecurity\\n##   Kayla Lawrence ⟨14⟩\\nResearch Associate\\n##   Mark Lundquist ⟨15⟩\\nHead of Late Stage Validation\\n##   Rosalind Schilizzi ⟨16⟩\\nResearch Associate\\n1 2⟨17⟩ 3⟨18⟩ … 17⟨19⟩ Next »⟨17⟩\\n## MORE\\n## News & Announcements\\n VIEW ALL ⟨20⟩\\n ![⟨21⟩ ](https://www.ochre-bio.com/</news>)\\n# GSK signs AI pact with Ochre to pinpoint source of liver diseases⟨22⟩\\n  * June 12, 2024\\n\\n\\n ![⟨23⟩ ](https://www.ochre-bio.com/</news>)\\n# UK biotech signs $1bn deal to develop liver disease drugs⟨22⟩\\n  * April 22, 2024\\n\\n\\n ![⟨24⟩ ](https://www.ochre-bio.com/</news>)\\n# Boehringer Ingelheim inks chronic liver disease research pact with Ochre Bio⟨22⟩\\n  * April 22, 2024\\n\\n\\n VIEW ALL ⟨20⟩\\n## PARTNERS & INVESTORS\\n## Ochre Ideas\\n VIEW ALL ⟨8⟩\\n## Think you’d like to **join our team?**\\nCheck out our open positions⟨25⟩ or ask us to hold your CV at jobs@ochre-bio.com\\n## Work at Ochre\\n WATCH VIDEO ⟨26⟩\\n![](https://live-ochrebio.pantheonsite.io/wp-content/uploads/2022/02/Group-4.svg)\\n## Subscribe for Updates⟨27⟩\\n**More** Careers⟨28⟩ News⟨20⟩\\n**Contact**\\n**Locations**\\nOxford, UK\\nTaipei City, Taiwan\\nNew York City, NY\\n**Contact** contact@ochre-bio.com\\n## Subscribe for Updates⟨27⟩\\n ⟨29⟩  Linkedin-in ⟨30⟩\\n© 2024 Ochre Bio\\n  * All Rights Reserved \\n  * All Regular Disclaimers Apply \\n  *  Privacy Policy  ⟨31⟩\\n\\n\\n' references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://www.ochre-bio.com/<#content>: Skip to content\\n⟨2⟩ https://www.ochre-bio.com/wp-content/uploads/2022/02/Group-4.svg:  ![\\n⟨3⟩ https://www.ochre-bio.com/</#what>: What\\n⟨4⟩ https://www.ochre-bio.com/</#why>: Why\\n⟨5⟩ https://www.ochre-bio.com/</#how>: How\\n⟨6⟩ https://www.ochre-bio.com/</#who>: Who\\n⟨7⟩ https://www.ochre-bio.com/</#more>: More\\n⟨8⟩ https://www.ochre-bio.com/</ideas>:  VIEW ALL \\n⟨9⟩ https://www.ochre-bio.com/<https:/gateway.euro.who.int/en/datasets/european-health-for-all-database/>: UK Health Security Agency, July 2021\\n⟨10⟩ https://www.ochre-bio.com/wp-content/uploads/2022/03/Group-18-1024x633.png:  ![\\n⟨11⟩ https://www.ochre-bio.com/<#>:  Load More \\n⟨12⟩ https://www.ochre-bio.com/<javascript:;>:  All \\n⟨13⟩ https://www.ochre-bio.com/<https:/www.ochre-bio.com/team/massoud-malang/>:  Massoud Malang \\n⟨14⟩ https://www.ochre-bio.com/<https:/www.ochre-bio.com/team/kayla-lawrence/>:  Kayla Lawrence \\n⟨15⟩ https://www.ochre-bio.com/<https:/www.ochre-bio.com/team/mark-lundquist/>:  Mark Lundquist \\n⟨16⟩ https://www.ochre-bio.com/<https:/www.ochre-bio.com/team/rosalind-schilizzi/>:  Rosalind Schilizzi \\n⟨17⟩ https://www.ochre-bio.com/<https:/www.ochre-bio.com/page/2/>: 2\\n⟨18⟩ https://www.ochre-bio.com/<https:/www.ochre-bio.com/page/3/>: 3\\n⟨19⟩ https://www.ochre-bio.com/<https:/www.ochre-bio.com/page/17/>: 17\\n⟨20⟩ https://www.ochre-bio.com/</news/>:  VIEW ALL \\n⟨21⟩ https://www.ochre-bio.com/wp-content/uploads/2021/12/fierce-biotech-logo-1.png:  ![\\n⟨22⟩ https://www.ochre-bio.com/<https:/www.ochre-bio.com/news/>: GSK signs AI pact with Ochre to pinpoint source of liver diseases\\n⟨23⟩ https://www.ochre-bio.com/wp-content/uploads/2024/05/17b6c9ac-7097-40fd-8f34-2f7117fd646b_aboutus-FT.jpg-1024x578.webp:  ![\\n⟨24⟩ https://www.ochre-bio.com/wp-content/uploads/2024/05/EndpointsNews_logo.jpg:  ![\\n⟨25⟩ https://www.ochre-bio.com/</careers/>: open positions\\n⟨26⟩ https://www.ochre-bio.com/<#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjU0NjciLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D>:  WATCH VIDEO \\n⟨27⟩ https://www.ochre-bio.com/<#elementor-action%3Aaction%3Dpopup%3Aopen%26settings%3DeyJpZCI6IjMzNDkiLCJ0b2dnbGUiOmZhbHNlfQ%3D%3D>: Subscribe for Updates\\n⟨28⟩ https://www.ochre-bio.com/</Careers-at-ochre>: Careers\\n⟨29⟩ https://www.ochre-bio.com/<https:/twitter.com/OchreBio?s=20&t=idTeGMQtVFOqBVlpDeMepA>:  \\n⟨30⟩ https://www.ochre-bio.com/<https:/www.linkedin.com/company/ochre-bio/>:  Linkedin-in \\n⟨31⟩ https://www.ochre-bio.com/</privacy-policy>:  Privacy Policy  \\n' fit_markdown='' fit_html=''",
  "generated_description": "**Ochre Bio** is a promising biotechnology company founded in 2019, situated in Oxford, United Kingdom. Known for its forward-thinking approach, the company specializes in developing RNA medicines targeting chronic liver diseases. This venture is particularly timely, given that chronic liver disease is increasingly recognized as a leading cause of premature death globally.\n\nPart of the Y Combinator Batch W20, Ochre Bio operates with a dedicated team of about 50 skilled professionals. Their mission is clear: to use human models to generate significant genomic and phenotypic data, creating innovative RNA therapies to address critical challenges in liver health. The statistics are alarming—chronic liver disease not only affects millions but is also the only condition among the top ten global killers that is on the rise.\n\nWhat sets Ochre Bio apart is its advanced scientific methodology. They employ a powerful combination of computational and multi-omic technologies to dive deep into the complexities of liver biology, proving themselves capable of quickly turning human data into potential therapies—moving from target to validated lead in weeks, not years.\n\nThe company is backed by a strong scientific team with decades of experience in genomics and drug discovery, reinforcing their commitment to tackling unmet medical needs for patients with late-stage liver disease. As they continue to push the boundaries of what's possible in RNA therapeutics, Ochre Bio is positioned as a key player in the future of liver disease treatment.\n\nFor more information, you can visit their [website](https://www.ochre-bio.com/)."
}